Last reviewed · How we verify
Alcohol 50%
Alcohol 50% is a marketed product by Tanta University, primarily indicated for the prevention of infection in minor injuries. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the lack of revenue data and key trial results, which may limit the drug's market visibility and investor confidence.
At a glance
| Generic name | Alcohol 50% |
|---|---|
| Sponsor | Tanta University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Prevention of infection in minor injuries
Common side effects
Key clinical trials
- Effect of Nutritional Ketosis on Alcohol Metabolism (PHASE2, PHASE3)
- Moderate Alcohol Consumption and Heart Function in Patients With a Recent Myocardial Infarction (NA)
- Tritordeum-based Foods for IBS Symptoms (NA)
- Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep (PHASE3)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Hemodynamic Resuscitation Guided by Non-Invasive Mean Systemic Filling Pressure to Prevent Acute Kidney Injury in Septic Shock (NA)
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (PHASE2)
- Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alcohol 50% CI brief — competitive landscape report
- Alcohol 50% updates RSS · CI watch RSS
- Tanta University portfolio CI